Clinical Trial Update: A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010) [Phase 3]

View source ↗

Summary

Phase III trial update for a two-dose multivalent HPV vaccine (V503) in 9-14 year-olds compared to 16-26 year-olds; completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-related Diseases
• Human Papillomavirus Infection

Drugs mentioned

• V503

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Human Papillomavirus Infection | Phase 3 | Status: COMPLETED | Results posted: 2016-04-26